Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
HealthDay News — Subthalamic deep brain stimulation (DBS) is an effective long-term therapy for Parkinson disease (PD), according to a study published online September 15 in JAMA Neurology.
Readers, many with Parkinson’s, respond to an article about Sue Goldie, who has the disease. Also: Tears over Trump’s America ...
Weekly intramuscular injections of rotigotine extended-release microspheres are linked to significant symptom improvement in ...
The world's largest-ever clinical trial of treatments to slow or stop the progression of Parkinson's disease has launched, ...
Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...
Clinical Trials Arena on MSN
Bayer’s cell therapy shows 3-year improvement in Phase I Parkinson’s trial
The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.
Background: Glioblastoma multiforme (GBM; WHO Grade 4) is an aggressive brain tumor that invariably recurs after surgical resection, chemoradiation, and adjuvant chemotherapy. Treatment is limited, in ...
Researchers caught Parkinson’s proteins drilling tiny holes in brain cells. The discovery could explain how the disease ...
TUESDAY, Oct. 7, 2025 (HealthDay News) — Deep brain stimulation (DBS) implants can provide long-term relief for people with ...
A large international team of researchers has found that deep brain stimulation in the subthalamic nucleus continues to help people with Parkinson’s disease even five years after treatment. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback